North America’s medical devices industry saw a rise of 0.8% in overall deal activity during Q3 2019, when compared to the four-quarter average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 243 deals worth $9.14bn were announced for the region during Q3 2019, against the last four-quarter average of 241 deals.
Of all the deal types, venture financing saw most activity in Q3 2019 with 175, representing a 72.02% share for the region.
In second place was M&A with 57 deals, followed by private equity deals with 11 transactions, respectively capturing a 23.5% and 4.5% share of the overall deal activity for the quarter.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $7.48bn, while venture financing and private equity deals totalled $1.34bn and $329.1m, respectively.
North America medical devices industry deals in Q3 2019: Top deals
The top five medical devices deals accounted for 69.3% of the overall value during Q3 2019.
The combined value of the top five medical devices deals stood at $6.34bn, against the overall value of $9.14bn recorded for the quarter.
The top five medical devices industry deals of Q3 2019 tracked by GlobalData were:
1) Exact Sciences’ $2.8bn acquisition of Genomic Health
2) The $1.17bn acquisition of BioTek Instruments by Agilent Technologies
3) Siemens Healthineers’ $1.1bn acquisition of Corindus Vascular Robotics
4) The $775m acquisition of Hu-Friedy Manufacturing by Cantel Medical
5) Stryker’s acquisition of GYS Tech and Mobius Imaging for $500m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.